Background: The C-reactive protein–albumin–lymphocyte (CALLY) index
is a novel inflammatory biomarker, and its association with the prognosis of
coronary artery disease (CAD) after percutaneous coronary intervention (PCI) has
not previously been studied. Therefore, this study aimed to investigate the
effect of using the CALLY index on adverse outcomes in CAD patients undergoing
PCI. Methods: From December 2016 to October 2021, we consecutively
enrolled 15,250 CAD patients and performed follow-ups for primary endpoints
consisting of all-cause mortality (ACM) and cardiac mortality (CM). The CALLY
index was computed using the following formula: (albumin lymphocyte)/(C-reactive protein
(CRP) 10). The average duration of the
follow-up was 24 months. Results: A total of 3799 CAD patients who had
undergone PCI were ultimately enrolled in the present study. The patients were
divided into four groups according to the CALLY index quartiles: Q1
(0.69, n = 950), Q2 (0.69–2.44, n = 950), Q3 (2.44–9.52, n = 950), and
Q4 (9.52, n = 949). The low-Q1 group had a significantly higher prevalence of
ACM (p 0.001), CM (p 0.001), major adverse cardiac
events (MACEs) (p = 0.002), and major adverse cardiac and
cerebrovascular events (MACCEs) (p = 0.002). Kaplan–Meier analysis
revealed that a low CALLY index was significantly linked with adverse outcomes.
After univariate and multivariate Cox regression analysis, the risk of ACM, CM,
MACEs, and MACCEs decreased by 73.7% (adjust hazard risk [HR] = 0.263, 95% CI:
0.147–0.468, p 0.001), 70.6% (adjust HR = 0.294, 95% CI:
0.150–0.579, p 0. 001), 37.4% (adjust HR = 0.626, 95% CI:
0.422–0.929, p = 0.010), and 41.5% (adjust HR = 0.585, 95% CI:
0.401–0.856, p = 0.006), respectively, in the Q4 quartiles compared
with the Q1 quartiles. Conclusions: This study revealed that a decreased
CALLY index was associated with worse prognoses for CAD patients after PCI. The
categorization of patients with a decreased CALLY index could provide valuable
evidence for the risk stratification of adverse outcomes in CAD patients after
PCI. Clinical Trial Registration: The details are available at
http://www.chictr.org.cn (Identifier: NCT05174143).